杭州泰格医药科技股份有限公司 2019 年年度报告全文 杭州泰格医药科技股份有限公司 2019 年年度报告 2020 年 04 月 1 杭州泰格医药科技股份有限公司 2019 年年度报告全文 第一节重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真实、准确、完整，不存在虚假记载、误导性 陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人曹晓春、主管会计工作负责人 Jun Gao （高峻）及会计机构负责人(会计主管人员)余国云声明：保证年度 报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 无 公司经本次董事会审议通过的利润分配预案为：以 748,450,333 为基数，向全体股东每 10 股派发现金红利 2.78 元（含 税），送红股 0 股（含税），以资本公积金向全体股东每 10股转增 0 股。 2 杭州泰格医药科技股份有限公司 2019 年年度报告全文 目录 | --- | |-------------------------------------------| | | | 第一节 重要提示、目录和奉义 | | 第二节 公司简介和主 ...

Dividend Distribution - The company plans to distribute a cash dividend of 3.50 CNY (including tax) for every 10 shares, based on a total of 493,170,705 shares[4]. - The company has proposed a stock bonus of 5 shares for every 10 shares held[2]. - The total cash dividend, including other methods such as share repurchase, amounts to 420,734,734.55 RMB, representing 89.10% of the net profit attributable to ordinary shareholders[102]. - The company’s distributable profit for the period is 1,010,702,290.44 RMB, with the cash dividend total accounting for 100% of the profit distribution[96]. - The cash dividend for 2017 was 100,035,307.40 RMB, which was 33.23% of the net profit attributable to ordinary shareholders[102]. - The cash dividend for 2016 was 50,017,653.70 RMB, representing 35.56% of the net profit attributable to ordinary shareholders[102]. - The company has a clear and transparent cash dividend policy, ensuring the protection of minority shareholders' rights[96]. - The company’s capital reserve will increase by 5 shares for every 10 shares held, in addition to the cash dividend distribution[100]. Financial Performance - The company's operating revenue for 2018 was approximately ¥2.30 billion, representing a 36.37% increase compared to ¥1.69 billion in 2017[17]. - The net profit attributable to shareholders for 2018 was approximately ¥472.18 million, a 56.86% increase from ¥301.01 million in 2017[17]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥357.06 million, up 48.83% from ¥239.90 million in 2017[17]. - The net cash flow from operating activities for 2018 was approximately ¥522.24 million, reflecting a 65.81% increase from ¥314.97 million in 2017[17]. - The total assets at the end of 2018 were approximately ¥4.28 billion, a 19.44% increase from ¥3.58 billion at the end of 2017[17]. - The net assets attributable to shareholders at the end of 2018 were approximately ¥2.67 billion, a 7.13% increase from ¥2.49 billion at the end of 2017[17]. - The basic earnings per share for 2018 was ¥0.9440, representing a 54.22% increase from ¥0.6121 in 2017[17]. - The diluted earnings per share for 2018 was also ¥0.9440, consistent with the basic earnings per share[17]. - The weighted average return on equity for 2018 was 17.52%, an increase of 3.78% from 13.74% in 2017[17]. Operational Highlights - The company is positioned as a leading Contract Research Organization (CRO), providing comprehensive clinical research services for pharmaceutical and medical device companies[23]. - The company has completed over 1,340 clinical trials and 880 domestic registration affairs, showcasing extensive project experience across various medical fields[29]. - As of the end of 2018, the company participated in nearly 100 varieties and 166 projects of domestic innovative drug clinical trials, including 28 new biological product projects[30]. - The company has established a service network with 95 domestic service points covering over 730 clinical trial institutions and 11 overseas offices[29]. - The company has established strategic partnerships with several innovative pharmaceutical companies, focusing on areas such as diabetes, rare diseases, and oncology[34]. Investment and Acquisitions - The company made several strategic investments, including acquiring 100% of Concord for $4.3192 million in 2018[47]. - The company has received investment income from various equity transfers, amounting to ¥126,926,483.99 in 2018, compared to ¥48,906,000.13 in 2017[21]. - The company has invested in developing new systems, including Clinflash IRT and Clinflash Safety, to enhance its one-stop clinical trial service system[37]. Research and Development - R&D expenses surged by 77.23% year-on-year to ¥88,025,353.33, driven by increased project R&D spending[52]. - R&D investment accounted for 3.83% of total revenue, with a total R&D expenditure of ¥88,025,353.33[55]. - The number of R&D personnel increased to 426, representing 10.93% of the total workforce[55]. Governance and Compliance - The company has established a structured governance framework, with a board of directors and committees functioning in accordance with legal and regulatory requirements[178]. - The audit committee oversees internal and external audits, ensuring the integrity of financial information and compliance with regulations[182]. - The company has not faced any significant discrepancies in governance practices compared to regulatory standards set by the China Securities Regulatory Commission[182]. - The independent directors did not raise any objections regarding company matters during the reporting period[186]. Shareholder Structure - Major shareholders include Ye Xiaoping with 24.82% (124,122,733 shares) and Cao Xiaochun with 8.75% (43,766,500 shares) of the total shares[154]. - The company has a total of 13,608 shareholders at the end of the reporting period[153]. - The total number of shares held by directors, supervisors, and senior management at the end of the reporting period is 188,482,553 shares[164]. Risk Management - The company is addressing risks related to quality control, policy changes, and human resources in the clinical trial sector[91]. - The company emphasizes the importance of understanding the differences between plans, forecasts, and commitments[4]. - The company has committed to ensuring the accuracy and completeness of the financial report, with all board members present for the meeting[3].

杭州泰格医药科技股份有限公司 2018 年第三季度报告全文 杭州泰格医药科技股份有限公司 2018 年第三季度报告 2018 年 10 月 1 杭州泰格医药科技股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 2 杭州泰格医药科技股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 4,077,889,908.87 | 3,583,167,950.81 | | 13.81% | | 归属于上市公司股东的净资产 | 2,770,811,883.57 | 2,491,046,293.20 | | 11.23% | | （元） | | | | | | | ...

Financial Performance - Total revenue for the first half of 2018 reached ¥1,032,770,121.02, an increase of 38.96% compared to ¥743,194,526.63 in the same period last year[23]. - Net profit attributable to shareholders was ¥218,653,138.20, representing an 82.78% increase from ¥119,629,504.03 year-on-year[23]. - Net profit after deducting non-recurring gains and losses was ¥189,339,905.84, up 80.90% from ¥104,666,640.61 in the previous year[23]. - Operating cash flow net amount was ¥198,771,385.56, an increase of 80.57% compared to ¥110,080,902.84 in the same period last year[23]. - Basic earnings per share rose to ¥0.4372, an increase of 82.78% from ¥0.2392 in the previous year[23]. - Total assets at the end of the reporting period were ¥3,955,501,709.16, a 10.39% increase from ¥3,583,167,950.81 at the end of the previous year[23]. - Net assets attributable to shareholders increased to ¥2,672,147,216.00, up 7.27% from ¥2,491,046,293.20 at the end of the previous year[23]. - The weighted average return on net assets was 8.42%, an increase of 2.09% compared to 6.33% in the previous year[23]. - The company's main business revenue reached 1,031.996 million CNY, representing a year-on-year growth of 38.99%[30]. - The net profit attributable to the parent company was 218.6531 million CNY, an increase of 82.78% compared to the previous year[30]. Operational Highlights - The report includes a detailed discussion and analysis of operational conditions and risks faced by the company[6]. - The company has multiple wholly-owned and controlled subsidiaries, enhancing its operational capabilities across various regions[13]. - The company is actively involved in the development of new products and technologies to strengthen its competitive position in the market[12]. - The company has established a one-stop service capability for medical device projects, enhancing efficiency across various stages from testing to clinical research[31]. - The company completed the acquisition of a CRO company in Romania, expanding its service capabilities in Europe[31]. - The company has established strategic partnerships with over 1,500 clinical trial institutions, enhancing its service network for domestic and international pharmaceutical clients[39]. - The company participated in over 150 innovative drug clinical studies, covering multiple therapeutic areas including oncology and cardiovascular diseases[36]. - The company is actively addressing clinical research bottlenecks by assisting over 20 medical institutions in building Phase I clinical research capabilities[31]. Compliance and Governance - The board of directors, supervisors, and senior management confirm the report's content is true, accurate, and complete, assuming legal responsibility for any misrepresentation or omissions[4]. - All directors attended the board meeting to review this report[5]. - The report outlines the company's commitment to maintaining compliance with regulatory standards in clinical research and drug development[12]. - The company does not have any discrepancies in net profit and net assets between international and Chinese accounting standards during the reporting period[24]. - There were no significant litigation or arbitration matters during the reporting period[100]. - The company did not experience any penalties or rectification issues during the reporting period[101]. Investment and Capital Strategy - The company plans not to distribute cash dividends, issue bonus shares, or increase share capital from reserves[7]. - The company plans to issue non-public shares to specific investors as part of its capital strategy[15]. - The company has committed to invest RMB 60,780.00 million for the acquisition of 100% equity in Jietong Tairui[71]. - The company reported a total investment of ¥228,821,469.24 during the reporting period, a decrease of 67.83% compared to the previous year's investment of ¥713,748,444.00[59]. - The company raised a total of RMB 499,999,990.64 from a non-public offering of 37,425,149 shares at a price of RMB 13.36 per share, with a net amount of RMB 475,799,990.64 after expenses[67]. - The company approved a non-public offering of up to 30,000,300 shares, raising RMB 629,999,999.30, with a net amount of RMB 607,799,999.30 after expenses[70]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 15,702[139]. - The largest shareholder, Ye Xiaoping, holds 24.82% of shares, totaling 124,122,733 shares, with a decrease of 10,000,000 shares during the reporting period[139]. - The second-largest shareholder, Cao Xiaochun, holds 8.75% of shares, totaling 43,766,500 shares, with no change during the reporting period[139]. - The company’s foreign shareholding stands at 8,703,360 shares, which is 1.74% of the total shares[134]. - The company’s domestic natural person shareholding decreased slightly from 143,888,755 to 143,180,305 shares, a change of approximately 0.49%[134]. Future Outlook - The company plans to continue expanding its market presence and investing in new product development to sustain growth in the upcoming periods[167]. - The management highlighted ongoing efforts in research and development to enhance product offerings and improve operational efficiency[167]. - The company aims to improve the efficiency of raised fund usage through strategic adjustments in investment projects[77]. - The company is focusing on expanding its domestic market and increasing orders for innovative drug research and development[88]. - The company is enhancing its capabilities by building a full industry service chain and adjusting its business direction based on market conditions[88].

Financial Performance - Total revenue for Q1 2018 reached ¥473,152,543.43, an increase of 33.16% compared to ¥355,332,310.97 in the same period last year[8] - Net profit attributable to shareholders was ¥95,904,393.84, representing a significant increase of 121.07% from ¥43,382,366.27 year-on-year[8] - The net profit after deducting non-recurring gains and losses was ¥69,168,786.31, up 60.86% from ¥42,999,701.69 in the previous year[8] - Basic earnings per share rose to ¥0.19, reflecting an increase of 111.11% compared to ¥0.09 in the same period last year[8] - The company's operating revenue for the first quarter reached ¥473.15 million, an increase of 33.16% compared to the same period last year[29] - Net profit for the quarter was ¥99.56 million, representing a growth of 93.20% year-on-year[34] - Cash and cash equivalents increased by 29.90% from the beginning of the period, totaling ¥697.25 million[25] - The average gross margin improved to 44.93%, up from 42.80% in the previous year[30] - The company reported a 50.61% increase in prepaid accounts, totaling ¥47.29 million, due to new project prepayments[25] - The total profit for the current period was ¥115,892,430.88, compared to ¥70,668,975.97 in the previous period, reflecting an increase of approximately 63.9%[61] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,934,263,847.30, a 9.80% increase from ¥3,583,167,950.81 at the end of the previous year[8] - Total current assets increased to ¥1,568,270,602.98 from ¥1,345,590,415.39, representing a growth of approximately 16.6%[52] - Cash and cash equivalents rose to ¥697,245,196.79 from ¥536,751,436.16, an increase of about 30%[52] - Accounts receivable increased to ¥750,410,758.09 from ¥631,686,778.14, reflecting a growth of approximately 18.8%[52] - Total non-current assets grew to ¥2,365,993,244.32 from ¥2,237,577,535.42, marking an increase of about 5.7%[53] - Total current liabilities increased to ¥921,717,607.73 from ¥715,490,708.45, a rise of about 28.8%[54] - Short-term borrowings rose to ¥414,841,668.25 from ¥242,444,628.71, reflecting an increase of approximately 71.1%[54] - Total liabilities increased to ¥968,237,151.93 from ¥764,176,707.04, representing a growth of about 27%[54] - Total equity attributable to shareholders increased to ¥2,639,495,480.61 from ¥2,503,535,618.23, marking a growth of approximately 5.4%[55] Cash Flow - The company reported a net cash flow from operating activities of ¥85,686,214.33, a decrease of 3.71% from ¥88,989,020.53 in the previous year[8] - Cash generated from operating activities was ¥412,155,605.23, compared to ¥345,584,976.32 in the previous period, representing an increase of approximately 19.2%[68] - The total cash inflow from investment activities was ¥71,364,845.38, down from ¥130,289,945.55 in the previous year, resulting in a net cash flow from investment activities of -¥85,080,926.90[70] - Cash inflow from financing activities reached ¥213,877,655.54, significantly higher than ¥76,673,280.00 in Q1 2017, leading to a net cash flow from financing activities of ¥172,314,358.70[70] - The ending balance of cash and cash equivalents increased to ¥690,727,907.46, compared to ¥434,495,712.57 at the end of Q1 2017[70] Shareholder Information - The total number of common shareholders at the end of the reporting period is 14,069[17] - The largest shareholder, Ye Xiaoping, holds 26.82% of the shares, totaling 134,122,733 shares, with 100,592,050 shares pledged[17] - The second-largest shareholder, Cao Xiaochun, holds 8.75% of the shares, totaling 43,766,500 shares, with 32,824,875 shares pledged[17] - The company has not conducted any repurchase transactions among its top shareholders during the reporting period[18] Business Strategy and Development - The company aims to enhance its business capabilities to meet the increasing demand for clinical trials and maintain its competitive edge in the CRO industry[15] - The company is focusing on expanding its business in clinical trial data management and statistical services to mitigate regulatory risks[13] - The company has established a comprehensive business development team to enhance customer satisfaction and attract new clients[12] - The company is implementing targeted training programs to retain clinical trial professionals and improve management capabilities[14] - The company has a strategy to ensure that its service quality and professional level meet international research standards[15] - The company is preparing to undertake high-level MRCT (Multi-Regional Clinical Trials) business, aligning service quality with international research standards[15] - The company is focusing on expanding its market presence and enhancing its service offerings in the clinical trial sector[42] Investment and Acquisitions - The company made significant investments in new projects, including investments in Hainan Haiyi, Suzhou Yixin, and Croley Martell Holdings, leading to a net cash outflow from investment activities of ¥8.51 million[33] - The acquisition of Fangda Pharmaceutical resulted in an expected benefit of RMB 8.5774 million, but the actual benefit was impacted by an investment loss of RMB -3.7294 million from Frontida[41] - The acquisition of Beiyirenzhi generated an income of RMB 1.5584 million, which did not meet the expected benefit due to ongoing improvements in market pricing and cost control[41] - The acquisition of Jietong Tairui reported an income of RMB 7.5624 million, which fell short of the expected benefit due to increased project workload and costs[42] - The company plans to utilize excess raised funds of RMB 27.7932 million for the acquisition of Fangda Pharmaceutical and other operational needs[41] Risks and Challenges - The company faces risks related to quality control, project progress delays due to regulatory checks, and reliance on major clients[11][12] - The company has committed to not providing further financial assistance to related parties after the repayment of the current borrowings[48] - The company has no violations regarding external guarantees during the reporting period[45] - There are no significant changes in net profit expected compared to the same period last year[44]